WAVE LIFE SCIENCES LTD. Increase (Decrease) in Accounts Payable and Accrued Liabilities
WAVE LIFE SCIENCES LTD. (WVE) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$3.10 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2019-08-06
- WAVE LIFE SCIENCES LTD. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-06-30 was $3.36M, a 89.79% increase year-over-year.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-03-31 was -$6.47M.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2018-12-31 was $5.22M, a 96.72% increase year-over-year.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2018-09-30 was $1.42M, a 18.34% decline year-over-year.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accounts payable and accrued liabilities for fiscal 2018 was $5.86M, a 28.88% increase from fiscal 2017.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accounts payable and accrued liabilities for fiscal 2017 was $4.55M, a 98.17% increase from fiscal 2016.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accounts payable and accrued liabilities for fiscal 2016 was $2.30M, a 759.93% increase from fiscal 2015.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accounts payable and accrued liabilities for fiscal 2015 was $267.00K, a 34.88% decline from fiscal 2014.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2019-06-30 | $3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$3.10M 10-Q · filed 2019-08-06 | $2.11M derived: sum of 3 quarters · filed 2019-08-06 | $3.53M derived: sum of 4 quarters · filed 2019-08-06 |
| 2019-03-31 | -$6.47M 10-Q · filed 2019-05-10 | -$1.25M derived: sum of 2 quarters · filed 2019-05-10 | $166.00K derived: sum of 3 quarters · filed 2019-05-10 | $1.94M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-12-31 | $5.22M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $6.63M derived: sum of 2 quarters · filed 2019-03-01 | $8.40M derived: sum of 3 quarters · filed 2019-08-06 | $5.86M 10-K · filed 2019-03-01 |
| 2018-09-30 | $1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $3.19M derived: sum of 2 quarters · filed 2019-08-06 | $647.00K 10-Q · filed 2018-11-09 | $3.30M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-06-30 | $1.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$769.00K 10-Q · filed 2019-08-06 | $1.88M derived: sum of 3 quarters · filed 2019-08-06 | $3.62M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | -$2.54M 10-Q · filed 2019-05-10 | $111.00K derived: sum of 2 quarters · filed 2019-05-10 | $1.84M derived: sum of 3 quarters · filed 2019-05-10 | $2.55M derived: sum of 4 quarters · filed 2019-05-10 |
| 2017-12-31 | $2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $4.39M derived: sum of 2 quarters · filed 2019-03-01 | $5.09M derived: sum of 3 quarters · filed 2019-03-01 | $4.55M 10-K · filed 2019-03-01 |
| 2017-09-30 | $1.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $2.44M derived: sum of 2 quarters · filed 2018-11-09 | $1.90M 10-Q · filed 2018-11-09 | $1.71M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $701.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $164.00K 10-Q · filed 2018-08-09 | -$24.00K derived: sum of 3 quarters · filed 2019-03-01 | $1.25M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | -$537.00K 10-Q · filed 2018-05-09 | -$725.00K derived: sum of 2 quarters · filed 2019-03-01 | $551.00K derived: sum of 3 quarters · filed 2019-03-01 | $1.43M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | -$188.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $1.09M derived: sum of 2 quarters · filed 2019-03-01 | $1.97M derived: sum of 3 quarters · filed 2019-03-01 | $2.30M 10-K · filed 2019-03-01 |
| 2016-09-30 | $1.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $2.15M derived: sum of 2 quarters · filed 2017-11-09 | $2.48M 10-Q · filed 2017-11-09 | $2.82M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-06-30 | $879.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $1.21M 10-Q · filed 2017-08-09 | $1.55M derived: sum of 3 quarters · filed 2018-03-12 | $1.83M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-03-31 | $329.00K 10-Q · filed 2017-05-10 | $669.00K derived: sum of 2 quarters · filed 2018-03-12 | $951.00K derived: sum of 3 quarters · filed 2018-03-12 | $847.00K derived: sum of 4 quarters · filed 2018-03-12 |
| 2015-12-31 | $340.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $622.00K derived: sum of 2 quarters · filed 2018-03-12 | $518.00K derived: sum of 3 quarters · filed 2018-03-12 | $267.00K 10-K · filed 2018-03-12 |
| 2015-09-30 | $282.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $178.00K derived: sum of 2 quarters · filed 2016-11-09 | -$73.00K 10-Q · filed 2016-11-09 | $473.00K derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | -$104.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$355.00K 10-Q · filed 2016-08-15 | $191.00K derived: sum of 3 quarters · filed 2017-03-16 | |
| 2015-03-31 | -$251.00K 10-Q · filed 2016-05-16 | $295.00K derived: sum of 2 quarters · filed 2017-03-16 | ||
| 2014-12-31 | $546.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $410.00K 10-K · filed 2017-03-16 | ||
| 2014-09-30 | -$136.00K 10-Q · filed 2015-12-17 | |||
| 2013-12-31 | $78.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |